

REPORT OF THE COMMITTEE OF INDEPENDENT DIRECTORS ('COMMITTEE') OF STRIDES PHARMA SCIENCE LIMITED ('COMPANY') AT ITS MEETING HELD ON SEPTEMBER 25, 2023, RECOMMENDING THE SCHEME OF ARRANGEMENT AMONGST STRIDES PHARMA SCIENCE LIMITED ("STRIDES" OR "TRANSFEROR COMPANY 1" OR "DEMERGED COMPANY 1" OR "COMPANY") AND STERISCIENCE SPECIALTIES PRIVATE LIMITED ("STERISCIENCE" OR "TRANSFEROR COMPANY 2" OR "DEMERGED COMPANY 2") AND STELIS BIOPHARMA LIMITED ("STELIS" OR "TRANSFEREE COMPANY" OR "RESULTING COMPANY") AND THEIR RESPECTIVE SHAREHOLDERS ("DRAFT SCHEME")

Present:

#	Name of Committee Members	Designation
1.	S. Sridhar	Independent Director & Chairperson of the Committee
2.	Homi Rustam Khusrokhan	Independent Director
3.	Dr. Kausalya Santhanam	Independent Director

1. Background

- 1.1. A meeting of the Committee of Independent Directors of Strides Pharma Science Limited ("**Company/ Strides**") was held on September 25, 2023, to, *inter alia*, consider and if thought fit, recommend to the Board of Directors of the Company ("**Board**"), the Scheme of Arrangement amongst Strides Pharma Science Limited ("Strides" or "Transferor Company 1" or "Demerged Company 1") and Steriscience Specialties Private Limited ("Steriscience" or "Transferor Company 2" or "Demerged Company 2") and Stelis Biopharma Limited ("Stelis" or "Transferee Company" or "Resulting Company"), and their respective shareholders ("**Draft Scheme**"), pursuant to the provisions of Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("Act") and the rules made thereunder.
- 1.2. Strides is a global pharmaceutical company headquartered in Bengaluru, India and specialises in developing and manufacturing niche finished dosage formulations. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's product portfolio encompasses a range of technically complex pharmaceutical products, including liquids, creams, ointments, soft gels, sachets, tablets, and modified-release dosage formats. Its expertise lies in the production of 'difficult to manufacture' products. In addition, Strides boasts a dedicated research and development facility in India with global filing capabilities, enabling continuous innovation and growth. Operating in over 100 countries, Strides has a robust global manufacturing footprint spanning eight facilities across four continents, including five US FDA-approved sites.
- 1.3. Steriscience is engaged in the business of development, manufacturing, marketing and distribution of niche pharmaceuticals products such as injectables for various markets. Steriscience focuses on creating value-added sterile injectables that bridge the gap at hospitals by streamlining workflows, reducing wastage of key resources, and increasing efficiency that solves for challenges of healthcare professionals across the globe, and also offers contract development and manufacturing services in relation to the same.
- 1.4. Stelis is engaged in research, development, manufacture and commercialisation of biological drug products in various injectable formats. It is a leading global biopharmaceutical contract development and manufacturing organization with extensive biologics, biosimilars, and vaccine research capabilities and offers end-to-end contract development and manufacturing services across all phases of pre-clinical and clinical development and commercial supply of biologics.



1.5. This report of the Committee is made in compliance with the requirement of the Master Circular No. SEBI/ HO/ CFD/ POD-2/ P/ CIR/ 2023/ 93 dated June 20, 2023, (“SEBI Circular”), issued by the Securities Exchange and Board of India (“SEBI”). In terms of the SEBI Circular, a report from the Committee is required, recommending the draft Scheme, after taking into consideration, *inter alia*, that the draft Scheme is not detrimental to the shareholders of the listed entity.

1.6. **Following documents were placed before the Committee for its consideration:**

- i. the Draft Scheme;
- ii. Valuation Report dated September 25, 2023, issued by PwC Business Consulting Services LLP, a Registered Valuer (Securities or Financial Assets) IBBI Registered Valuer No. IBBI/ RV-E/ 02/ 2022/ 158, recommending the Share Entitlement Ratios (as defined hereunder) for the Draft Scheme (“**Valuation Report**”);
- iii. Fairness Opinion dated September 25, 2023, prepared by Jefferies India Private Limited, an Independent SEBI registered (Category-I) Merchant Banker (Registration Number – INM000011443), confirming that the Share Entitlement Ratios in the Valuation Report are fair to the Companies and their respective shareholders and (“**Fairness Opinion**”); and
- iv. Draft Auditors’ certificate, confirming that the accounting treatment contained in the Draft Scheme in clause 12 is in compliance with the applicable accounting standards specified by the Central Government under Section 133 of the Act read with applicable rules, and/or the accounting standards issued by the Institute of Chartered Accountants of India and other generally accepted accounting principles

2. **Observations of the Committee on the Scheme**

2.1. **Rationale for the Scheme**

The Independent Directors noted the rationale of the Scheme which is as follows:

“The Board of Directors of the Companies involved in the Scheme are intending to build a one-of-a-kind specialty pharmaceutical Contract Development and Manufacturing (‘CDMO’) powerhouse with capabilities in biologics, complex injectables, sterile injectables, including other complex drug delivery systems. In this regard, it is proposed to combine the Identified CDMO Business of Strides and the Identified CDMO Business of Steris under Stelis. The new platform will be able to offer development and manufacturing services covering platform technologies, specialty injectables, complex generics, biosimilars, and biologics. While this will be strategically valuable, it will also be the first platform of its kind in India, spanning capabilities and services that only very few global companies have to offer.”

The proposed Scheme would inter alia have the following benefits:

1. *The consolidation of the Identified CDMO Business of Strides and Identified CDMO Business of Steris, with Stelis, will result in integration synergies and enable better supervision of the business.*
2. *The consolidation will allow the management to devise, implement and pursue independent business strategies for the contract development and manufacturing business which will enable a wider scope for independent collaboration, investment opportunities and expansion.*



✓

3. *The consolidation will enhance business potential and result in an increased capability to offer a wider portfolio of products with a diversified resource base and deeper client relationships.*
4. *The consolidation would result in efficient utilisation of the infrastructure facilities and optimum utilisation of the available resources.*
5. *Further, the synergies arising out of the consolidation will lead to enhancement of net worth of the combined business and enhancement in earnings and cash flow would optimize the value of the Stelis and consequently enhance the shareholder's value.*
6. *The consolidation will create and enhance stakeholder's value by unlocking the intrinsic value of the Identified CDMO Business of Strides and Identified CDMO Business of Steriscience, on listing of shares of Stelis.*
7. *Moreover, the Scheme is expected to increase the long-term value for the shareholders of all the Companies and other stakeholders."*

In view of the aforesaid, the Committee has considered and proposed this Scheme and matters incidental thereto pursuant to the provisions of Sections 230 to 232 and other applicable provisions, if any of the Companies Act, 2013.

2.2. **Salient Features of the Scheme**

The Independent Directors Committee considered and observed the following salient features in relation to the Draft Scheme:

- i. The Draft Scheme is divided into parts, with key parts being:
 - a) Demerger of the Demerged Undertaking 1 (as more explicitly defined in the Scheme) from Strides into Stelis;
 - b) Demerger of the Demerged Undertaking 2 (as more explicitly defined in the Scheme) from Steriscience into Stelis;
- ii. Appointed Date for the Scheme shall be April 1, 2024 or such other date as may be approved by the jurisdictional National Company Law Tribunal(s), ("NCLT"/ "Tribunal"), with effect from which the Scheme will be deemed to be effective in the manner described in the Scheme.
- iii. The effectiveness of this Scheme is conditional upon and subject to the following:
 - a) receipt of 'Observation Letter' or 'No-Objection Letter' from the BSE Limited and National Stock Exchange of India Limited ("**Stock Exchanges**") on the Draft Scheme, as required under applicable laws;
 - b) approval from requisite majority of such classes of shareholders, secured creditors and unsecured creditors of each of the Companies which are part of the Scheme and such other persons/ authorities, as may be required under applicable laws or as may be directed by the NCLT;



A handwritten blue checkmark.

- c) the Scheme being approved by the Shareholders of Strides, provided that the votes cast by public shareholders of the Company in favour of the Scheme are more than the number of votes cast by public shareholders against it, under the SEBI Circular;
 - d) sanction of the Scheme by the jurisdictional NCLT under the relevant provisions of the Act;
 - e) compliance with such conditions as may be imposed by the NCLT;
 - f) receipt of such other approvals including, approvals of any governmental authority as may be necessary under applicable laws or under any material contract to make the Scheme or the relevant Part of the Scheme effective or on the expiry of any statutory time period pursuant to which such approval is deemed to have been granted; and
 - g) certified copy of the order of the NCLT sanctioning the Scheme being filed with the jurisdictional Registrar of Companies by each of the Companies.
- iv. Upon the Scheme becoming operative on the Effective Date, with effect from the Appointed Date, issue of shares pursuant to the transfer of the Demerged Undertaking 1 and Demerged Undertaking 2 shall be accounted for in the books of the Companies in accordance with the accounting treatment prescribed under the Draft Scheme.
- v. The following share entitlement ratios have been determined:
- a) for the allotment of equity shares of the Resulting Company, having face value of INR 1/- each to the shareholders of Demerged Company 1 as on the Record Date 1 (as defined in the Scheme), in consideration for the demerger:

“1 (one) equity share of Transferee Company (of INR 1/- each fully paid up) for every 2 (Two) equity shares of Transferor Company 1 (of INR 10/- each fully paid up).”
 - b) for the allotment of equity shares of the Resulting Company, having face value of INR 1/- each to the shareholders of Demerged Company 2 as on the Record Date 2 (as defined in the Scheme), in consideration for the demerger:

“1,515 (One Thousand Five Hundred and Fifteen) equity shares of Transferee Company (of INR 1/- each fully paid up) for every 1 (one) equity shares of Transferor Company 2 (of INR 10/- each fully paid up).”

2.3. Valuation Methods Evaluated for the Share Entitlement Ratio

Committee noted that the Valuers have used multiple methods of valuation including Income Approach and Market Approach and attributed appropriate weights to values for arriving at the Share Entitlement Ratios.

Entitlement Ratios have been arrived at on the basis of a relative equity valuation (on a per share basis) of Stelis and the Identified CDMO Business of Strides and Steriscience as per the Income and Market approach, respectively.



✓

2.4. **Cost-Benefit Analysis of the Scheme**

Implementation of the scheme will involve incurring costs including, administrative/ statutory levy(ies), fees payable to financial/ legal advisors etc.

Considering the rationale and synergies detailed in the above clauses, the consolidation of CDMO business under Stelis will enable the Companies to concentrate their resources and managerial bandwidth entirely to their respective businesses which would lead to optimum utilization of resources and enable focused strategy, better coordination and cohesiveness in their working and assist in standardisation of their business process.

As a result, the long-run benefit derived by the shareholders would foreshadow the cost incurred towards implementation of the scheme.

2.5. **Scheme Not Detrimental to the Shareholders of the Company**

Committee members discussed and deliberated upon the rationale and salient features of the Scheme. It was noted that there are common promoters in the Companies.

As on date, Karuna Business Solutions LLP and Tenshi Pharmaceuticals Private Limited (“collectively referred to as the Promoters”) own 29.93% and the Company and Arco Lab Private Limited, a wholly owned subsidiary of the Company, together own 30.74% on fully diluted basis in Stelis. Further, as on date, Tenshi Pharmaceuticals Private Limited owns majority stake in Steriscience.

In terms of the Scheme, equity shares of the Resulting Company are proposed to be issued and allotted to the shareholders of the Company and Transferor Company 2 respectively.

In view of the aforesaid paragraph and in terms of Paragraphs 10(b)(i) and 10(b)(ii) of the SEBI Circular, the Scheme shall be acted upon only if the votes cast by the public shareholders of the Company in favour of the Scheme are more than the number of votes cast by the public shareholders against it.

Consideration as set forth in the Draft Scheme will be discharged on an ‘arms’ length basis’. Share entitlement ratios for the shares to be allotted pursuant to the Scheme are based on the Valuation Report and the Fairness Opinion. The aforementioned Valuation Report and Fairness Opinion have duly been considered by the Committee.

Considering the above, Committee was of the informed opinion that the Draft Scheme is in the best interest of shareholders and is not detrimental to their interest, including interest of the minority shareholders of the Company.

3. **Recommendations of the Committee**

Committee interacted with the Registered Valuer, Merchant Banker, Transaction Advisors and the Due Diligence teams and after due deliberations and due consideration of all the terms of the Draft Scheme, the Valuation Report, the rationale provided above, the Fairness Opinion and the specific points mentioned above, Committee is of the opinion that the Draft Scheme is not detrimental to the interest of shareholders of the Company; and further recommends the Draft Scheme for favourable consideration and approval of the Board, Stock Exchanges, SEBI and other appropriate authorities.



This report of the Committee is made in order to comply with the requirements of the SEBI Circular after considering the necessary documents.

By Order of the Committee of Independent Directors of
Strides Pharma Science Limited



S. Sridhar
Independent Director &
Chairperson of the Committee
DIN: 00004272



Date: September 25, 2023